Navigation Links
MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
Date:3/18/2008

- Company Initiates Phase 2a Trial in Patients with Stable Asthma and

Exercise-Induced Bronchoconstriction -

GAITHERSBURG, Md., March 18 /PRNewswire/ -- MedImmune today announced that its clinical program studying an investigational treatment targeting interleukin-9 (IL-9) has advanced with the start of a new trial in patients with asthma. The company initiated a Phase 2a clinical trial designed to assess the potential of its anti-IL-9 monoclonal antibody (MAb), MEDI-528, in patients with stable asthma and exercise-induced bronchoconstriction. This trial is the fourth study of this antibody in patients with asthma.

"Commencing this trial is a promising step in the clinical development of MEDI-528, as preclinical data has suggested that blocking IL-9 may provide clinical benefit for patients with asthma," said Barbara White, vice president, clinical development, inflammatory disease. "We look forward to continuing to work with our network of collaborative researchers to discover and assess novel pathologies and approaches to inflammatory diseases."

The goal of this clinical trial is to assess the safety and tolerability of multiple fixed escalating doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction. The study will also assess the effect of the antibody on exercise challenge testing, as well as the pharmacokinetics and immunogenicity of the investigational treatment. Enrollment of this randomized, double-blind, placebo-controlled trial has commenced at Northeast Medical Research Associates, Inc. and the study is expected to expand to additional sites throughout the United States and Canada. Preliminary safety results from an ongoing Phase 2 trial support the continued development of the antibody in patients with mild-to-moderate asthma.

About Interleukin-9

IL-9 has been associated with symptoms of asthma. It is one of at least 29 naturally occurring interleukins in the human body. Overexpression of IL-9 in animal models has been shown to result in many features of asthma, including increased airway inflammation and hyperreactivity. Blocking the actions of IL-9 has been shown to reduce the increased airway inflammation and airway hyperresponsiveness seen in animal models of asthma. MedImmune is conducting research to evaluate the potential to use MAbs targeting IL-9 to treat or prevent symptomatic, moderate-to-severe, persistent asthma.

About Asthma

Asthma is a chronic disease of the airways that may cause wheezing, breathlessness, chest tightness and coughing. According to the U.S. Centers for Disease Control and Prevention (CDC), more than 30 million Americans reported having a history of asthma in 2003, including nine million children. About 20 million said they currently had asthma. In 2000, the CDC reported that there were more than 10 million asthma-related outpatient visits to private physician offices and hospital clinics. The National Institutes of Health (NIH) have estimated asthma-related healthcare costs in the U.S. at $14 billion annually.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on cardiovascular/gastrointestinal disease, neuroscience, oncology, infection, respiratory disease and inflammation. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
2. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
3. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
4. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
8. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
9. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
10. Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research
11. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... July 24, 2017  Diplomat Pharmacy, Inc. (NYSE: ... its second quarter 2017 operating results on Monday, August ... to follow at 5:00 p.m. ET. ... to a live broadcast of the conference call by ... participant code 51641230 approximately 15 minutes prior to the ...
(Date:7/20/2017)... 2017  Prime Therapeutics LLC (Prime) released this statement from ... today,s Institute for Clinical and Economic Review,s (ICER) public ... and value of abuse-deterrent formulations (ADF) of opioids. Prime was ... the meeting. "The ... to the use of abuse-deterrent formulations (ADF) in opioids in ...
(Date:7/14/2017)... VEGAS , July 13, 2017 It should ... United States is in the midst of a ... Control , since 1999, the number of overdose deaths from ... "resulting in over half a million dead from 2001 to ... codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a compelling ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... 2017 , ... Patients with missing teeth now have the ... from Dr. Alejandro Kovacs. Dr. Kovacs is a board-certified periodontist and prosthodontist who ... dental implants in Longview, TX. , During traditional dental implant ...
(Date:7/27/2017)... ... 27, 2017 , ... TransPanel Volume 4 is a collection of animating panel ... exclusive features transitions that contain between 2 and 6 animated panels. Change the direction ... menus. TransPanel Volume 4 makes editing easy in Final Cut Pro X. , TransPanel ...
(Date:7/27/2017)... Clara, CA (PRWEB) , ... July 27, 2017 ... ... announces the addition of a secure cloud-based polysomnography (PSG) distributed scoring solution to ... support accelerated diagnostics and sleep care management. The speed and functionality of scoring ...
(Date:7/27/2017)... ... 2017 , ... SSCI, a division of Albany Molecular Research, ... representing a milestone achievement. , As an industry-leading provider of ... served as expert and fact witnesses to assist our clients to perform infringement ...
(Date:7/27/2017)... ... ... Angeles leg of the US movie premier of the Man in the Camo Jacket will ... Davis Theater inside the Grammy Museum Located in downtown Los Angeles in the LA Live ... musician, Mike Peters (of The Alarm), his rise to fame, battle with cancer and inspiring ...
Breaking Medicine News(10 mins):